Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03877796 · ClinicalTrials.gov registry record
Clinical Pre-screening Protocol for Ovarian Cancer
A clinical trial of Ovarian Cancer, sponsored by Allarity Therapeutics.
- Recruiting
- Registry status
- 60
- Enrollment target
- 5
- Study locations
NCT03877796 is a study of Ovarian Cancer that is actively recruiting participants, run by Allarity Therapeutics. The registered enrollment target is 60 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03877796, a study of Ovarian Cancer, is actively recruiting participants, sponsored by Allarity Therapeutics.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Conditions Studied
Interventions
- DEVICE Drug Response Predictor® (DRP)
Study Locations (5)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Oklahoma
- OU Health Stephenson Cancer Center - Oklahoma City
Washington
- Swedish Center for Research and Innovation - Seattle
Scotland
- Beatson West of Scotland Cancer Centre - Glasgow
Other
- Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-04-11 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03877796
The ClinicalTrials.gov registry entry for NCT03877796 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Allarity Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Drug Response Predictor® (DRP) is the first listed.
NCT03877796 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Oklahoma, Washington.
Frequently Asked Questions
What is clinical trial NCT03877796 about?
NCT03877796 is a clinical study titled "Clinical Pre-screening Protocol for Ovarian Cancer". The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity The...
What is the current status of trial NCT03877796?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2019-04-11. Estimated completion is 2026-12.
What conditions does trial NCT03877796 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT03877796?
The interventions under investigation include: Drug Response Predictor® (DRP) (DEVICE).
Who is sponsoring clinical trial NCT03877796?
This trial is sponsored by Allarity Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03877796 being conducted?
This trial has 5 study locations across Massachusetts, Oklahoma, Washington, Scotland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.